查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球人类微生物组市场：按产品（药物、益生菌、益生元）按应用（治疗、诊断）按疾病（癌症、胃肠道疾病、传染病）按类型（□、LBP、FMT））预测（至 2029 年）
市场调查报告书
商品编码
1283515

全球人类微生物组市场：按产品（药物、益生菌、益生元）按应用（治疗、诊断）按疾病（癌症、胃肠道疾病、传染病）按类型（□、LBP、FMT））预测（至 2029 年）

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 183 Pages | 订单完成后即时交付

价格
简介目录

全球人类微生物组市场规模预计到 2029 年将达到 17 亿美元，高于 2023 年的 3 亿美元，在预测期内以 36.1% 的复合年增长率增长。

推动人类微生物组市场增长的主要因素是对个性化医疗的需求激增，而对自然和整体方法的需求不断增长预计将推动市场增长。 然而，由于对微生物相互作用的了解有限，预计市场增长将在一定程度上受到限制。

“按应用划分，治疗领域在人类微生物组市场中所占份额最大”

在应用方面，由于人们越来越了解微生物组在维持人类健康方面的关键作用，因此治疗药物将在 2023 年主导市场。 该市场还受到製药和生物技术公司投资增加以及对个性化医疗需求不断增长的推动。

“按疾病划分，传染病领域在人类微生物组市场中所占份额最大”

按病种分，2023年传染病领域占比更大。 这一细分市场的增长得益于对微生物组在人类健康中的作用的日益了解以及先进测序和生物信息学技术的发展，以发现用于预防和治疗传染病的新的基于微生物组的疗法。人们认为这是因为已经打开了表征的方式

“北美：人类微生物组市场份额最大”

北美在人类微生物组市场中所占份额最大。 北美地区的很大一部分归因于该地区成熟的医疗和生物技术产业，拥有先进的基础设施、尖端的研究机构以及致力于微生物组研究的生物技术公司和 CRO 的强大生态系统。这可能是由于 北美是领先的学术机构、研究医院和私营公司的所在地，这些公司拥有致力于微生物组研究的项目和专业知识，为人类微生物组市场的增长做出了贡献。

“亚太地区”：人类微生物组市场增长最快的地区

预计亚太地区人类微生物组市场在预测期内将以最高复合年增长率增长。 这是由于人们越来越意识到微生物组在健康和疾病中的重要性、对个性化医疗的需求不断增长、测序技术的进步等等。 亚太地区人类微生物组市场的另一个主要驱动因素是该地区庞大且迅速老龄化的人口。

内容

第一章介绍

第二章研究方法论

第 3 章执行摘要

第 4 章重要注意事项

第 5 章市场概述

  • 简介
  • 市场动态
    • 司机
    • 约束因素
    • 机会
    • 任务
  • 技术分析
  • 影响客户业务的趋势/颠覆
  • 供应炼和价值链分析
  • 生态系统分析
  • 波特的五力分析
  • 监管分析
  • 价格分析
  • 主要会议和活动（2023 年）
  • 主要利益相关者和采购标准

第 6 章人类微生物组市场：按应用分类

  • 简介
  • 治疗
  • 诊断

第 7 章人类微生物组市场：按疾病分类

  • 简介
  • 感染
  • 胃肠道疾病
  • 内分泌代谢疾病
  • 癌症
  • 其他疾病

第 8 章人类微生物组市场：副产品

  • 简介
  • 药物
  • 诊断测试
  • 益生菌
  • 益生元
  • 其他产品

第 9 章人类微生物组市场：按类型分类

  • 简介
  • 细菌联合移植 (BCT)/粪便微生物群移植 (FMT)
  • 多□
  • 活生物製品 (LBP)
  • 其他类型

第 10 章人类微生物组市场：按地区

  • 简介
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 其他地区

第11章竞争格局

  • 简介
  • 公司采用的主要策略
  • 公司评估象限
  • 商业评估象限：初创公司/中小企业
  • 竞争情景和趋势

第12章公司简介

  • 主要公司
    • SERES THERAPEUTICS, INC.
    • ENTEROME
    • 4D PHARMA PLC
    • INTERNATIONAL FLAVORS & FRAGRANCES, INC.
    • OPTIBIOTIX HEALTH PLC
    • FERRING PHARMACEUTICALS
    • SYNLOGIC, INC.
    • SECOND GENOME INC.
    • VEDANTA BIOSCIENCES, INC.
    • YSOPIA BIOSCIENCE
    • FLIGHTPATH BIOSCIENCES, INC.
    • FINCH THERAPEUTICS GROUP, INC.
    • AOBIOME THERAPEUTICS
    • BIOGAIA
    • QUANTBIOME, INC. (DBA OMBRE)
  • 其他企业
    • VIOME LIFE SCIENCES, INC.
    • BIOHM HEALTH
    • DAYTWO
    • ALTAS BIOMED
    • BIONE VENTURES PRIVATE LIMITED
    • LUXIA SCIENTIFIC
    • METABIOMICS
    • SUN GENOMICS
    • SEED HEALTH
    • GNUBIOTICS SCIENCES

第13章 附录

简介目录
Product Code: BT 2711

The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key factors driving the growth of the human microbiome market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.

The human microbiome market has been segmented based on product, type, application, disease, and region.

"By application, the therapeutics segment accounted for the largest share of the human microbiome market"

Based on application, the human microbiome market is categorized into therapeutics, and diagnostics. The therapeutics segment dominated the market in 2023, owing to the increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.

"By disease, infectious diseases segment accounted for the largest share in the human microbiome market"

Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. In 2023, the infectious diseases segment accounted for a larger share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the role of the microbiome in human health and the development of advanced sequencing and bioinformatics techniques are paving the way for the discovery and characterization of novel microbiome-based therapeutics for the prevention and treatment of infectious diseases.

"North America: the largest share of the human microbiome market"

North America accounted for the largest share of the human microbiome market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in microbiome research. The presence of top academic institutions, research hospitals, and private companies in North America with dedicated microbiome research programs and expertise has contributed to the growth of the human microbiome market.

"Asia Pacific: The fastest-growing region in the human microbiome market."

The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific human microbiome market is the region's large and rapidly aging population.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 60% and Demand Side 40%
  • By Designation: Executives - 40%, Research Scientists- 30%, and Managers - 30%
  • By Country: North America- 22%, Europe- 42%, Asia Pacific- 11%, Rest of the World- 25%

Prominent Players

  • Seres Therapeutics, Inc. (US)
  • Enterome (France)
  • 4D pharma plc (UK)
  • International Flavors & Fragrances Inc. (US)
  • OptiBiotix Health Plc (UK)
  • Ferring Pharmaceuticals (Switzerland)
  • Synlogic, Inc. (US)
  • Second Genome, Inc. (US)
  • Vedanta Biosciences, Inc. (US)
  • YSOPIA Bioscience (France)
  • FlightPath Biosciences, Inc. (US)
  • Finch Therapeutics Group, Inc. (US)
  • AOBiome Therapeutics (US)
  • BioGaia (Sweden)
  • Quantbiome, Inc. (dba Ombre) (US)
  • Viome Life Sciences, Inc. (US)
  • BIOHM Health (US)
  • DayTwo (US)
  • Atlas Biomed (UK)
  • Bione Ventures Private Limited (India)
  • Luxia Scientific (France)
  • Metabiomics (US)
  • Sun Genomics (US)
  • Seed Health (US)
  • Gnubiotics Sciences (Switzerland)

Research Coverage:

This report provides a detailed picture of the human microbiome market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (drugs, diagnostics tests, probiotics, prebiotics, and other products), application (therapeutic, and diagnostics), disease (infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, and other diseases), type (Bacterial consortia transplantation (BCT)/ fecal microbiota transplantation(FMT), peptides, live biotherapeutic products, and other types), and region (North America, Europe, Asia Pacific, and Rest of the World). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall human microbiome market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers"

  • Analysis of key drivers (collaborative efforts between microbiome industry and academia for microbiome research, surging demand for personalized medicine, and rising awareness about importance of human microbiome), restraints (adverse impact of complex regulatory policies on commercialization of microbiomes), opportunities (increased collaboration of key players and small innovative companies collaborating to work on new microbiome technologies, and advancements in sequencing and bioinformatics), and challenges (low patient adoption rate of microbiome-based therapies, and complexities involved in development of microbiome therapies) influencing the growth of the human microbiome market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the human microbiome market.
  • Market Development: Comprehensive information about lucrative markets- the report analyses the human microbiome market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human microbiome market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK) among others in the human microbiome market strategies. The report also helps stakeholders understand the pulse of the animal research model market and provides them information on key market drivers, restraints, challenges and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY
  • 1.6 RESEARCH LIMITATIONS
  • 1.7 STAKEHOLDERS
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
    • FIGURE 4 HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION)
    • FIGURE 5 HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023-2029)
    • FIGURE 6 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.3 MARKET DATA ESTIMATION AND TRIANGULATION
    • 2.3.1 DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 INDUSTRY INSIGHTS
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
    • FIGURE 9 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION)
    • FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION)
    • FIGURE 11 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 HUMAN MICROBIOME MARKET OVERVIEW
    • FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
  • 4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023)
    • FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
  • 4.3 HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Collaborative efforts between microbiome industry and academia for microbiome research
      • 5.2.1.2 Surging demand for personalized medicine
      • 5.2.1.3 Rising awareness about importance of human microbiome
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased collaboration of key players and small innovative companies to work on new microbiome technologies
    • TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Slow patient adoption of microbiome-based therapies
      • 5.2.4.2 Complexities involved in development of microbiome therapies
  • 5.3 TECHNOLOGY ANALYSIS
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.5 SUPPLY AND VALUE CHAIN ANALYSIS
    • 5.5.1 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS
    • FIGURE 17 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS
    • 5.5.2 VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET
    • FIGURE 18 HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 19 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF BUYERS
    • 5.7.4 BARGAINING POWER OF SUPPLIERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 REGULATORY ANALYSIS
    • 5.8.1 FDA APPROVALS
    • 5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PRICING ANALYSIS
    • TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
    • 5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS IN 2023
    • 5.10.1 HUMAN MICROBIOME CONFERENCES (2023)
    • TABLE 12 HUMAN MICROBIOME CONFERENCES (2023)
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 20 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
    • 5.11.2 HUMAN MICROBIOME MARKET: BUYING CRITERIA
    • FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS

6 HUMAN MICROBIOME MARKET, BY APPLICATION

  • 6.1 INTRODUCTION
    • TABLE 13 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • 6.2 THERAPEUTICS
    • 6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET
    • TABLE 14 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 16 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 6.3 DIAGNOSTICS
    • 6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
    • TABLE 18 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 20 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2029 (USD MILLION)

7 HUMAN MICROBIOME MARKET, BY DISEASE

  • 7.1 INTRODUCTION
    • TABLE 22 HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
  • 7.2 INFECTIOUS DISEASES
    • 7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET
    • TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
    • TABLE 24 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 26 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.3 GASTROINTESTINAL DISEASES
    • 7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET
    • TABLE 28 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 29 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 30 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.4 ENDOCRINE & METABOLIC DISORDERS
    • 7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET
    • TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS
    • TABLE 33 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 34 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 35 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.5 CANCER
    • 7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET
    • TABLE 37 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 38 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 39 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.6 OTHER DISEASES
    • TABLE 41 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 42 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 43 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)

8 HUMAN MICROBIOME MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
    • TABLE 45 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION))
  • 8.2 DRUGS
    • 8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET
    • TABLE 46 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.3 DIAGNOSTIC TESTS
    • 8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET
    • TABLE 50 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.4 PROBIOTICS
    • 8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY
    • TABLE 54 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.5 PREBIOTICS
    • 8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH
    • TABLE 58 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.6 OTHER PRODUCTS
    • TABLE 62 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 63 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 64 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)

9 HUMAN MICROBIOME MARKET, BY TYPE

  • 9.1 INTRODUCTION
    • TABLE 66 HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
  • 9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
    • 9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH
    • TABLE 67 HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.3 PEPTIDES
    • 9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET
    • TABLE 71 HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.4 LIVE BIOTHERAPEUTIC PRODUCTS
    • 9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET
    • TABLE 75 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 9.5 OTHER TYPES
    • TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023-2029 (USD MILLION)

10 HUMAN MICROBIOME MARKET, BY REGION

  • 10.1 INTRODUCTION
    • FIGURE 22 HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION)
    • TABLE 83 HUMAN MICROBIOME MARKET, BY REGION, 2023-2029 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 85 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 87 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Spike in research activities to drive market
    • TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 89 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 90 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 91 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Rising prevalence of chronic diseases to boost microbiome research
    • TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 93 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 94 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 95 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.2.3 NORTH AMERICA: RECESSION IMPACT
  • 10.3 EUROPE
    • TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 97 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 98 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 99 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Rapid increase in government funding to propel market
    • TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 101 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 102 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 103 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Significant government investments in genomics research to propel growth
    • TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 105 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 106 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 107 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Rise in microbiome sequencing startups to boost growth
    • TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE
    • TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 110 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 111 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 112 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.4 REST OF EUROPE
    • TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 114 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 115 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 116 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.3.5 EUROPE: IMPACT OF RECESSION
  • 10.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
    • TABLE 117 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Increasing R&D investments to drive growth
    • TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 123 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 124 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 125 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Growing geriatric population to present opportunities for market growth
    • TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 127 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 128 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 129 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Increasing prevalence of chronic diseases to support growth
    • TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 131 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 132 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 133 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 135 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 136 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 137 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 10.5 REST OF THE WORLD
    • TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 139 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
    • TABLE 140 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 141 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023-2029 (USD MILLION)
    • 10.5.1 REST OF THE WORLD: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY STRATEGIES ADOPTED BY PLAYERS
    • FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 COMPANY EVALUATION QUADRANT
    • FIGURE 26 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022)
    • 11.3.1 STARS
    • 11.3.2 EMERGING LEADERS
    • 11.3.3 PERVASIVE PLAYERS
    • 11.3.4 PARTICIPANTS
  • 11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 11.4.1 PROGRESSIVE COMPANIES
    • 11.4.2 STARTING BLOCKS
    • 11.4.3 RESPONSIVE COMPANIES
    • 11.4.4 DYNAMIC COMPANIES
    • FIGURE 27 HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022)
    • 11.4.5 COMPETITIVE BENCHMARKING
      • 11.4.5.1 Human microbiome market: Detailed list of start-ups/SMEs
    • TABLE 142 HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES
      • 11.4.5.2 Human microbiome market: Competitive benchmarking of key players (start-ups/SMEs)
    • TABLE 143 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
  • 11.5 COMPETITIVE SCENARIO AND TRENDS
    • TABLE 144 HUMAN MICROBIOME MARKET: DEALS
    • 11.5.1 PRODUCT LAUNCHES
    • TABLE 145 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES
    • 11.5.2 EXPANSIONS
    • TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS

12 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 12.1 KEY PLAYERS
    • 12.1.1 SERES THERAPEUTICS, INC.
    • TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW
    • 12.1.2 ENTEROME
    • TABLE 148 ENTEROME: COMPANY OVERVIEW
    • 12.1.3 4D PHARMA PLC
    • TABLE 149 4D PHARMA: COMPANY OVERVIEW
    • FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022)
    • 12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
    • TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
    • FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022)
    • 12.1.5 OPTIBIOTIX HEALTH PLC
    • TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW
    • FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021)
    • 12.1.6 FERRING PHARMACEUTICALS
    • TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW
    • 12.1.7 SYNLOGIC, INC.
    • TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022)
    • 12.1.8 SECOND GENOME INC.
    • TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW
    • 12.1.9 VEDANTA BIOSCIENCES, INC.
    • TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW
    • 12.1.10 YSOPIA BIOSCIENCE
    • TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW
    • 12.1.11 FLIGHTPATH BIOSCIENCES, INC.
    • TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW
    • 12.1.12 FINCH THERAPEUTICS GROUP, INC.
    • TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW
    • FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022)
    • 12.1.13 AOBIOME THERAPEUTICS
    • TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW
    • 12.1.14 BIOGAIA
    • TABLE 160 BIOGAIA: COMPANY OVERVIEW
    • FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021)
    • 12.1.15 QUANTBIOME, INC. (DBA OMBRE)
    • TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 VIOME LIFE SCIENCES, INC.
    • 12.2.2 BIOHM HEALTH
    • 12.2.3 DAYTWO
    • 12.2.4 ALTAS BIOMED
    • 12.2.5 BIONE VENTURES PRIVATE LIMITED
    • 12.2.6 LUXIA SCIENTIFIC
    • 12.2.7 METABIOMICS
    • 12.2.8 SUN GENOMICS
    • 12.2.9 SEED HEALTH
    • 12.2.10 GNUBIOTICS SCIENCES
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.2 CUSTOMIZATION OPTIONS
  • 13.3 RELATED REPORTS
  • 13.4 AUTHOR DETAILS